Naftidrofuryl

Naftidrofuryl is used as a vasodilator in the treatment of peripheral and cerebral vascular disorders. Naftidrofuryl may be effective for relieving the pain of muscle cramps. ==Adverse effects==

Naftidrofuryl has been associated with nausea, abdominal pain and rash. ==Pharmacology==

Pharmacodynamics Naftidrofuryl acts as a selective antagonist of 5-HT2 receptors (with action as an inverse agonist of the 5-HT2A receptor specifically characterized). Pharmacokinetics The oral bioavailability of naftidrofuryl is 20 to 78% in different studies. The drug's plasma protein binding is 80%. It is metabolized in the liver. The elimination half-life of naftidrofuryl is 1.2 to 2hours. Its half-life is longer in the elderly than in younger people. The drug's duration of effects is 2 to 3hours and closely parallels circulating levels of naftidrofuryl. ==History==

Naftidrofuryl was first described in the scientific literature by at least 1966. ==Society and culture==

Names Naftidrofuryl is the generic name of the drug and its (, , , and . It is also known as naftidrofurile () or as nafronyl (. Naftidrofuryl is marketed under a variety of trade names, including Artocoron, Azunaftil, Di-Actane, Dusodril, Enelbin, Frilix, Gevatran, Iridus, Iridux, Luctor, Nafti, Naftilong, Naftodril, Nafoxal, Praxilene, Sodipryl Retard, Stimlor, and Vascuprax, among others. Availability Naftidrofuryl is marketed and used widely throughout the world. == See also ==